At the end
of the recruitment period, we expect to achieve a total
sample size of 25,000 patients with some stage of the disease.
This sample size would allow us to calculate a hazard
ratio (HR) of at least 1.5, with a power of greater than
99 % for progression-free survival comparing either across
treatment protocols or disease stages.